Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models a

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical findings on the treatment of prostate cancer models at the American Association for Cancer Research (AACR) conference. Halozyme is investigating its Pegylated-rHuPH20 enzyme (PEGrHuPH20) as a candidate for the systemic treatment of tumors rich in hyaluronan (HA) in combination with chemotherapy.

The studies explored the physiologic responses to enzymatic removal of HA-based matrices surrounding tumor cells in the tumor microenvironment of prostate tumors following systemic administration of its PEGrHuPH20 pre-clinical candidate. In animal pharmacokinetic models, PEGrHuPH20 demonstrated a more than 2,000-fold increase in plasma half-life compared to the unmodified enzyme. Prostate tumors were grown around the bone as a model of elevated interstitial fluid pressure (IFP). Treatment commenced when tumors had reached approximately 500 mm3 in size and pressure within the tumor had reached 30-40 mm Hg.

The objectives of these studies were to determine whether HA-dependent pericellular matrices produced in vitro and in vivo by hormone refractory prostate cancer cell line could be enzymatically depleted in prostate carcinoma xenografts following intravenous (IV) administration of the PEGrHuPH20 enzyme. The dose dependent effects of systemic enzyme treatment were evaluated by a combination of direct micropressure measurements, magnetic resonance imaging (MRI), ultrasound, immunohistochemistry, and determination of tumor water content. A summary of findings is as follows:

"These findings represent significant advancements towards our goal of understanding the role of HA in the tumor microenvironment and mechanism of action of PEGrHuPH20" said Gregory Frost, PhD, Halozyme's Vice President and Chief Scientific Officer. "By selectively decompressing tumor vessels, we may significantly improve tumor exposure and responses to chemotherapy regimens. These findings have facilitated our efficacy studies in combination with selected chemotherapy agents, which will be presented later this year as part of our overall development strategy for this new compound."

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the pre-clinical results of the company's pegylated rHuPH20 enzyme) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

SOURCE Halozyme Therapeutics, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.